Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Miripla Recommended for Approval for Hepatic Cancer
August 10, 2009
- SSP Revises Business Forecasts Upward
August 10, 2009
- Onglyza Approved by FDA as 2nd DPP-4 Inhibitor
August 10, 2009
- Drug Price Maintenance System Necessary: Dr Nishijima of LDP
August 10, 2009
- Draft Position Paper Released on BRONJ and Treatment with Bisphosphonates
August 10, 2009
- DPJ Supports Promotion of the Use of Generics: Dr Adachi
August 10, 2009
- SMUD to Become Operational to Monitor Use of Thalidomide Imported for Personal Use
August 10, 2009
- JPA Vice President Conditionally Supports Industry-Proposed Pricing System Reform
August 10, 2009
- Diabetes and Osteoporosis Are Related: Prof. Okazaki
August 10, 2009
- Industry Must Give Clearer Explanations about Need for NHI Pricing System Reform: Mr Kinoshita
August 10, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 10, 2009
- Marketing Authorization Holders Must Maintain Close Communication with Suppliers
August 10, 2009
- Hisamitsu to Increase Overseas Sales to 15% of Total Sales
August 10, 2009
- OMT Creates First Targeted Immunoglobulin Knockout Rats
August 10, 2009
- Takeda to Promote Wyeths Seltouch from October
August 10, 2009
- Comprehensive Clinical Trial Program Proposed in NDAs for Oral Antidiabetics
August 10, 2009
- Daiichi Sankyo to Launch Effient in the US in August
August 10, 2009
- REGULATORY NEWS IN BRIEF
August 10, 2009
- Zeria to Acquire Tillotts
August 10, 2009
- Introduce Financial Incentives to Promote Use of Generics: Mr Sawai of JGA
August 10, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…